6-18岁儿童大量苯海拉明摄入的频率
该回顾性时间序列研究利用美国国家毒物数据系统(NPDS)2016年1月1日至2023年12月31日6-18岁苯海拉明摄入记录,共24,358例,2020-2023年较2016-2019年增加34.3%。大量摄入(≥2,500 mg)占4.9%(1,190例),其占比从2016-2019年的4.6%升至2020-2023年的5.1%,估计季度变化0.03%(95%CI -0.01-0.06%)。大量摄入者住院率69.6% vs 非大量摄入26.2%(P<0.001),严重效应(危及生命症状、残留残疾或死亡)21.3% vs 1.0%,且更多使用机械通气、药物治疗和胃肠道去污。
要点
- 6-18岁苯海拉明摄入2020-2023年较2016-2019年增加34.3%,但大量(≥2,500 mg)摄入占比无显著上升(季度变化0.03%,95%CI -0.01-0.06%)。
- 大量摄入(≥2,500 mg)占全部摄入的4.9%(1,190/24,358),住院率69.6%,非大量摄入为26.2%(P<0.001)。
- 大量摄入者严重效应(危及生命症状、残留残疾或死亡)发生率为21.3%,非大量摄入为1.0%。
- 大量摄入者更多接受机械通气、药物治疗和胃肠道去污。
适用人群与场景
- 6-18岁儿童,2016年1月1日至2023年12月31日期间向美国国家毒物数据系统(NPDS)报告的苯海拉明摄入病例。
诊断标准与关键阈值
- 大量摄入定义为苯海拉明摄入量≥2,500 mg。
- 严重效应定义为危及生命症状、残留残疾或死亡。
处置流程与药物剂量
- 大量摄入者中69.6%需住院,非大量摄入者中26.2%需住院(P<0.001)。
- 大量摄入者较非大量摄入者更多使用机械通气、药物治疗和胃肠道去污。
研究设计与关键结果
- 回顾性时间序列研究,基于美国国家毒物数据系统(NPDS),纳入2016年1月1日至2023年12月31日6-18岁苯海拉明摄入病例共24,358例。
- 苯海拉明摄入病例数从2016-2019年到2020-2023年增加34.3%。
- 大量摄入(≥2,500 mg)共1,190例(4.9%);大量摄入占比从2016-2019年的4.6%升至2020-2023年的5.1%,估计季度变化0.03%(95%CI -0.01-0.06%)。
- 住院率:大量摄入组69.6% vs 非大量摄入组26.2%(P<0.001)。
- 严重效应(危及生命症状、残留残疾或死亡)发生率:大量摄入组21.3% vs 非大量摄入组1.0%。
- 大量摄入组较非大量摄入组更多使用机械通气、药物治疗和胃肠道去污。
证据类型、等级与局限
- 证据类型:基于美国国家毒物数据系统(NPDS)的回顾性时间序列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,大量苯海拉明摄入与更严重症状和更高水平医疗照护相关。
- 作者指出,2020年后大量摄入占比无显著增加,但苯海拉明摄入总数增加。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Intentional diphenhydramine ingestions increased in 2020 due to the Coronavirus pandemic and social media challenges. The purpose was to describe trends in frequency, management, and outcomes of massive (≥2,500 mg) and non-massive diphenhydramine ingestions in children from 2016-2023, which are prior to and after the COVID-19 and the TikTok® "Benadryl Challenge."
METHODS: This retrospective time-series utilized the National Poison Data System (NPDS)® records of diphenhydramine ingestions in patients 6-18 years of age between January 1, 2016-December 31, 2023. The primary objective was to evaluate the frequency of massive and non-massive diphenhydramine ingestions. Secondary objectives included comparison of frequency of diphenhydramine ingestions in 2016-2019 to 2020-2023, and comparison of outcomes and management of massive and non-massive ingestions. Bivariate comparisons were made using Chi-Square or Fisher's Exact tests, and interrupted time-series analysis and segmented linear regression models to compare rates of diphenhydramine ingestions between time periods.
RESULTS: There were 24,358 cases, with a 34.3% increase from 2016-2019 to 2020-2025. Of those, 1,190 cases (4.9%) were classified as massive ingestions. Massive ingestions increased from 4.6% to 5.1% of cases from 2016-2019 and 2020-2023, respectively, with an estimated quarterly change of 0.03% (95% CI: -0.01-0.06%). Inpatient admission was required in 69.6% and 26.2% of massive and non-massive ingestions, respectively (P <0.001). Massive ingestion resulted in major effects (i.e.,, life-threatening symptoms or residual disability or death) in 21.3% and 1.0% of cases, respectively, resulting in greater use of mechanical ventilation, pharmacologic therapies, and gastrointestinal decontamination.
DISCUSSION: Diphenhydramine ingestions increased from 2016-2023, but the percentage of massive ingestions was not statistically different prior to and after 2020. Management is variable, with a greater percentage of massive ingestion cases requiring inpatient admission and receiving pharmacologic treatment.
CONCLUSION: The percentage of massive diphenhydramine ingestions ranged from 2.7-6.7% of reported ingestions from 2016-2023, and the trend since 2020 was not significantly increased. Massive diphenhydramine ingestions are associated with more severe symptoms and higher levels of care.
参考来源
- Luke M, Johnson PN, Neely SB, et al. Frequency of massive diphenhydramine ingestions in children 6-18 years of age. Clin Toxicol (Phila). 2026. PMID: 42312630. doi:10.1080/15563650.2026.2680177
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。